The Series A round was co-led by Forbion and General Atlantic to support clinical trials and portfolio expansion.
"People living with obesity and its complications deserve better options at each stage of their treatment journey. These include oral therapies with less frequent dosing regimens, which have the potential for improved efficacy and tolerability, and innovative combination therapies for healthier weight loss and—equally importantly—maintenance of metabolically healthy weight. We created Verdiva Bio to accelerate the development of differentiated medicines that address these significant unmet medical needs."
The round was led by We Venture Capital and Cross-Border Impact Ventures to fund the global commercialisation of its liquid biopsy technology.
"Having developed blood-based proteomic tests for lung cancer for over two decades, I appreciate the difficulty of detecting cancers early through liquid biopsy. Convinced that OXcan’s unique approach can address this clinical need, I feel privileged to join the team. Together, our plan is to offer this novel technological approach to large markets worldwide to start a new era of early detection and improve patient outcomes."
— Heinrich Roder, Senior Vice President of Research and Development
Accelerate Ventures led the Series A round to support the expansion of Betmate and Engage Games.
"Kicking off 2025 with some incredible news: we’re closing our latest $2m funding round for Betmate and Engage Games, led by Accelerate Ventures, adding the latter were joined by world-class investors with backgrounds in sports, gaming, and betting."
Northern Gritstone leads Series A round into the Manchester-based manufacturing technology platform.
"Northern Gritstone is delighted to support Partful. This growing Manchester-based tech company has already won large OEM customers thanks to its technology and is set to create more jobs in its North of England team"
The funding round was led by EQT Life Sciences to support regulatory clearance and manufacturing development.
"Securing this Series A financing is a crucial milestone for Nua Surgical. It not only provides the capital needed to advance our product but also brings on board a group of experienced investors who share our vision for transforming maternal health. We are eager to leverage their expertise as we move towards commercialising SteriCISION."
